NFG
AVDL

Nations Financial Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Nations Financial Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,550
Closed -$163K – 660
2024
Q4 		$163K Buy
+15,550
New +$189K 0.01% 649

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Nations Financial Group's AVDL Position: Q1 2025 in Review

Nations Financial Group sold out of Avadel Pharmaceuticals (AVDL) in Q1 2025, closing a stake of 15,550 shares — an estimated $163K sold.

Nations Financial Group first reported a position in AVDL in Q4 2024 and held it in 1 quarter. The position peaked at $163K in Q4 2024. 175 funds tracked by Wall St. Rank hold AVDL as of Q1 2025.

  • Nations Financial Group reported no remaining Avadel Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Nations Financial Group sold 15,550 Avadel Pharmaceuticals shares in Q1 2025, an estimated $163K.
  • Nations Financial Group first reported a position in Avadel Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Nations Financial Group's Avadel Pharmaceuticals position peaked at $163K in Q4 2024.
  • 175 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2025.

Based on Nations Financial Group's 13F filing for Q1 2025, filed 13 May 2025.